Reaction
Tonsillar Hypertrophy reporting signals
As of the last recalculation, Tonsillar Hypertrophy appears in 1,649 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is TRIMETHOPRIM (PRR 16.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Trimethoprim | 15 | 16.2 | 16.2 |
| Lithium Carbonate | 16 | 12.0 | 12.0 |
| Infliximab-Dyyb | 26 | 11.4 | 11.4 |
| Anti-Thymocyte Globulin (Rabbit) | 7 | 11.0 | 11.0 |
| Somatropin | 60 | 10.7 | 10.7 |
| Canakinumab | 8 | 9.4 | 9.4 |
| Tranexamic Acid | 6 | 8.5 | 8.5 |
| Emicizumab | 5 | 5.1 | 5.1 |
| Asfotase Alfa | 4 | 5.0 | 5.1 |
| Bimekizumab | 6 | 3.6 | 3.6 |
| Voxelotor | 5 | 2.8 | 2.8 |
| Etonogestrel | 7 | 1.9 | 1.9 |